施贵宝宣布,其3期Excaliber-Rrmm研究评估Iberdomide与标准疗法联合治疗的结果显示,在复发或难治性多发性骨髓瘤患者中,微小残留病变阴性率获得显著改善。
施贵宝宣布,其3期Excaliber-Rrmm研究评估Iberdomide与标准疗法联合治疗的结果显示,在复发或难治性多发性骨髓瘤患者中,微小残留病变阴性率获得显著改善。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.